Wang Ging Kuo, Russell Corinna, Wang Sho-Ya
Department of Anesthesia, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, USA.
J Gen Physiol. 2003 Sep;122(3):365-74. doi: 10.1085/jgp.200308857. Epub 2003 Aug 11.
The antiarrhythmic agent flecainide appears beneficial for painful congenital myotonia and LQT-3/DeltaKPQ syndrome. Both diseases manifest small but persistent late Na+ currents in skeletal or cardiac myocytes. Flecainide may therefore block late Na+ currents for its efficacy. To investigate this possibility, we characterized state-dependent block of flecainide in wild-type and inactivation-deficient rNav1.4 muscle Na+ channels (L435W/L437C/A438W) expressed with beta1 subunits in Hek293t cells. The flecainide-resting block at -140 mV was weak for wild-type Na+ channels, with an estimated 50% inhibitory concentration (IC50) of 365 micro M when the cell was not stimulated for 1,000 s. At 100 micro M flecainide, brief monitoring pulses of +30 mV applied at frequencies as low as 1 per 60 s, however, produced an approximately 70% use-dependent block of peak Na+ currents. Recovery from this use-dependent block followed an exponential function, with a time constant over 225 s at -140 mV. Inactivated wild-type Na+ channels interacted with flecainide also slowly at -50 mV, with a time constant of 7.9 s. In contrast, flecainide blocked the open state of inactivation-deficient Na+ channels potently as revealed by its rapid time-dependent block of late Na+ currents. The IC50 for flecainide open-channel block at +30 mV was 0.61 micro M, right within the therapeutic plasma concentration range; on-rate and off-rate constants were 14.9 micro M-1s-1 and 12.2 s-1, respectively. Upon repolarization to -140 mV, flecainide block of inactivation-deficient Na+ channels recovered, with a time constant of 11.2 s, which was approximately 20-fold faster than that of wild-type counterparts. We conclude that flecainide directly blocks persistent late Na+ currents with a high affinity. The fast-inactivation gate, probably via its S6 docking site, may further stabilize the flecainide-receptor complex in wild-type Na+ channels.
抗心律失常药物氟卡尼似乎对疼痛性先天性肌强直和LQT-3/DeltaKPQ综合征有益。这两种疾病在骨骼肌或心肌细胞中均表现出微小但持续的晚钠电流。因此,氟卡尼可能因其疗效而阻断晚钠电流。为了研究这种可能性,我们在Hek293t细胞中对野生型和失活缺陷型rNav1.4肌肉钠通道(L435W/L437C/A438W)与β1亚基共表达时氟卡尼的状态依赖性阻断进行了表征。对于野生型钠通道,在-140 mV时氟卡尼的静息阻断较弱,当细胞在1000秒内未受到刺激时,估计50%抑制浓度(IC50)为365微摩尔。然而,在100微摩尔氟卡尼时,以低至每60秒1次的频率施加+30 mV的短暂监测脉冲,会产生约70%的峰钠电流使用依赖性阻断。从这种使用依赖性阻断中恢复遵循指数函数,在-140 mV时时间常数超过225秒。失活的野生型钠通道在-50 mV时与氟卡尼的相互作用也很缓慢,时间常数为7.9秒。相比之下,氟卡尼对失活缺陷型钠通道的开放状态有强力阻断作用,这通过其对晚钠电流的快速时间依赖性阻断得以揭示。在+30 mV时氟卡尼开放通道阻断的IC50为0.61微摩尔,恰好在治疗性血浆浓度范围内;结合速率常数和解离速率常数分别为14.9微摩尔-1秒-1和12.2秒-1。复极化至-140 mV时,氟卡尼对失活缺陷型钠通道的阻断恢复,时间常数为11.2秒,比野生型对应物快约20倍。我们得出结论,氟卡尼以高亲和力直接阻断持续性晚钠电流。快速失活门可能通过其S6对接位点,进一步稳定野生型钠通道中的氟卡尼-受体复合物。